Revolutionizing Cardiovascular Therapies:
Shaping the Future of Mitral and Tricuspid Innovations
Despite remarkable progress in aortic valve technologies, the mitral and tricuspid spaces remain underexplored, offering immense potential for innovation and impact. Millions of patients suffering from these diseases lack safe and effective treatment options, yet the advent of transcatheter therapies, driven by advances in imaging, AI, and device design, is transforming care with faster recovery and improved quality of life.
The Atrio Ventricular Academy Meeting (AVAM 2025) stands as a global platform for collaboration, knowledge exchange, and innovation. This year, the meeting will spotlight the groundbreaking opportunities in mitral and tricuspid therapies, exploring cutting-edge devices, clinical breakthroughs, and strategies to expand access worldwide.
By fostering interdisciplinary dialogue, addressing real-world challenges, and promoting tailored, patient-centered solutions, AVAM 2025 is poised to redefine standards of care and accelerate the adoption of life-saving technologies. Together, we are building a future where structural heart disease is met with precision, innovation, and global equity.
Looking forward seeing you in Bordeaux.
AVAM team
Pr Thomas Modine
MD, PhD, MBA
CHU de Bordeaux